23:43:19 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Initiator Pharma är verksamma inom bioteknik. Idag innehas störst affärsinriktning mot utveckling av läkemedelskandidater som används vid behandling av erektil dysfunktion hos män. Bolaget har för tillfället läkemedel ute på marknaden för patienter som inte svarar på PDE5i läkemedel. Initiator Pharma kom till via en spin-off från Saniona och har idag sitt huvudkontor i Åbyhøj.

Kalender

2023-12-17 Bokslutskommuniké 2022
2022-11-04 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-23 Ordinarie utdelning INIT 0.00 SEK
2022-05-20 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-18 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-31 Ordinarie utdelning INIT 0.00 SEK
2021-05-28 Årsstämma 2021
2021-05-25 Kvartalsrapport 2021-Q1
2021-05-11 Extra Bolagsstämma 2021
2021-02-19 Bokslutskommuniké 2020
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-25 Ordinarie utdelning INIT 0.00 SEK
2020-05-22 Årsstämma 2020
2020-05-22 Kvartalsrapport 2020-Q1
2020-02-21 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning INIT 0.00 SEK
2019-05-23 Kvartalsrapport 2019-Q1
2019-05-23 Årsstämma 2019
2019-02-22 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-28 Ordinarie utdelning INIT 0.00 SEK
2018-05-25 Årsstämma 2018
2018-05-25 Kvartalsrapport 2018-Q1
2018-03-01 Extra Bolagsstämma 2017
2018-02-21 Bokslutskommuniké 2017
2017-11-24 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-26 Kvartalsrapport 2017-Q1
2017-05-17 Ordinarie utdelning INIT 0.00 SEK
2017-05-16 Årsstämma 2017
2022-05-18 16:32:00

The MAR etiquette was included in the previously published press release by mistake

Today, 18 May 2022, the Extraordinary General Meeting of Initiator Pharma A/S (the “Company”) was held. Below follows a summary of the adopted resolutions. All resolutions were adopted with the required majority of votes.

Decision to authorise the Board of Directors to issue shares without pre-emption rights
The extraordinary general meeting resolved to authorise the Board of Directors to increase the share capital, at one or more times, with up to nominal DKK 279,999.93 without pre-emptive subscription rights for the Company’s existing shareholders. The extraordinary general meeting resolved, in accordance with the Board of Directors proposal, to adopt the authorisation as a new article 4aa in the articles of association with the following wording:

“The board of directors is authorised until the period ending 1 May 2023, at one or more times, by resolution of the board of directors to increase the share capital with up to nominal DKK 279,999.93 without pre-emptive subscription rights for the Company’s shareholders. Capital increases may be carried out by way of cash contribution. Capital increases may be carried out at market price or at a discount to market price.

The new shares issued based on this authorisation shall be negotiable instruments issued in the name of the holder and registered in the name of the holder in the Company’s register of shareholders. The new shares shall not have any restrictions as to their transferability and no shareholder shall be obliged to have the shares redeemed fully or partly. The shares will have the same rights as the existing shares. All other terms are set by the board of directors.”

Decision to authorise the Board of Directors to increase the share capital with pre-emptive subscription rights for the Company’s existing shareholders
The extraordinary general meeting resolved to authorise the Board of Directors to increase the share capital, at one or more times with up to nominal DKK 573,659.73 with pre-emptive subscription rights for the Company’s existing shareholders. The extraordinary general meeting resolved, in accordance with the Board of Directors proposal, to adopt the authorisation as a new article 4bb in the articles of association with the following wording:

“The board of directors is authorised until the period ending 1 May 2023, at one or more times, by resolution of the board of directors to increase the share capital with up to nominal DKK 573,659.73 with pre-emptive subscription rights for the Company’s shareholders. Capital increases may be carried out by way of cash contribution. Capital increases may be carried out at market price or at a discount to market price.

The new shares issued based on this authorisation shall be negotiable instruments issued in the name of the holder and registered in the name of the holder in the Company’s register of shareholders. The new shares shall not have any restrictions as to their transferability and no shareholder shall be obliged to have the shares redeemed fully or partly. The shares will have the same rights as the existing shares. All other terms are set by the board of directors.”

Copenhagen, 18 May 2022
Initiator Pharma A/S